2020
DOI: 10.1016/j.joca.2020.03.001
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis

Abstract: Objective: To evaluate the efficacy and safety of duloxetine in the treatment of patients with osteoarthritis (OA) or chronic low back pain (CLBP). Methods: Relevant randomized controlled trials (RCTs) were searched in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. Included RCTs compared the efficacy and safety of duloxetine vs placebo in the treatment of OA or CLBP. Weighted mean difference (WMD) were calculated for continuous outcomes while risk ratio … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
31
0
5

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 36 publications
(37 citation statements)
references
References 48 publications
1
31
0
5
Order By: Relevance
“…The analgesic effect of duloxetine in patients with centrally mediated pain due to OA is well documented. [10,25] From the results of this study, approaches to the pathology of CS may be important for hip OA patients with pain, particularly, pain at rest.…”
Section: Discussionmentioning
confidence: 90%
See 1 more Smart Citation
“…The analgesic effect of duloxetine in patients with centrally mediated pain due to OA is well documented. [10,25] From the results of this study, approaches to the pathology of CS may be important for hip OA patients with pain, particularly, pain at rest.…”
Section: Discussionmentioning
confidence: 90%
“…[8] In recent years, some treatments have been reported for OA patients with CS components. [8][9][10][11] While it is important to identify OA patients with CS components, the prevalence and characteristics of CS, especially in patients with hip OA, are not well understood.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, some treatments of OA pain related to CS components have been reported [8][9][10][11]. Duloxetine is a potent selective serotonin norepinephrine reuptake inhibitor that potentiates the descending inhibitory pain pathways in the central nervous system [24].…”
Section: Discussionmentioning
confidence: 99%
“…Patients with chronic pain with CS components have been reported to be resistant to conservative treatment, including traditional physiotherapy and pain medication [8]. In recent years, some treatments have been reported for OA patients with CS components [8][9][10][11]. While it is important to identify OA patients with CS components, the prevalence and characteristics of CS, especially in patients with hip OA, are not well understood.…”
Section: Introductionmentioning
confidence: 99%
“…14 As a standard treatment for administration of the analgesics, the recommended agents for neuropathic pain have been Pregabalin (evidence level 1A), duloxetine hydrochloride (Cymbalta) (1A), and Amitriptyline Hydrochloride (Tryptanol) (1B). 15 Duloxetine is categorized as serotonin and noradrenaline reuptake inhibitor (SNRI), that is effective for depressive state. It has been widely used for diabetic neuropathy.…”
mentioning
confidence: 99%